Serum eotaxin-1 is increased in extremely-low-birth-weight infants with bronchopulmonary dysplasia or death

Pediatr Res. 2015 Nov;78(5):498-504. doi: 10.1038/pr.2015.152. Epub 2015 Aug 13.

Abstract

Background: Early systemic inflammation in extremely-low-birth-weight (ELBW) infants is associated with an increased risk of bronchopulmonary dysplasia (BPD). Our objective was to identify circulating biomarkers and develop prediction models for BPD/death soon after birth.

Methods: Blood samples from postnatal day 1 were analyzed for C-reactive protein (CRP) by enzyme-linked immunosorbent assay and for 39 cytokines/chemokines by a multiplex assay in 152 ELBW infants. The primary outcome was physiologic BPD or death by 36 wk. CRP, cytokines, and clinical variables available at ≤24 h were used for forward stepwise regression and Classification and Regression Tree (CART) analysis to identify predictors of BPD/death.

Results: Overall, 24% developed BPD and 35% died or developed BPD. Regression analysis identified birth weight and eotaxin (CCL11) as the two most significant variables. CART identified FiO2 at 24 h (11% BPD/death if FiO2 ≤28%, 49% if >28%) and eotaxin in infants with FiO2 > 28% (29% BPD/death if eotaxin was ≤84 pg/ml; 65% if >84) as variables most associated with outcome.

Conclusion: Eotaxin measured on the day of birth is useful for identifying ELBW infants at risk of BPD/death. Further investigation is required to determine if eotaxin is involved in lung injury and pathogenesis of BPD.

Publication types

  • Observational Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Biomarkers / blood*
  • Birth Weight
  • Bronchopulmonary Dysplasia / blood*
  • Bronchopulmonary Dysplasia / diagnosis
  • Bronchopulmonary Dysplasia / mortality
  • C-Reactive Protein / analysis
  • Chemokine CCL11 / blood*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Hospital Mortality
  • Humans
  • Infant
  • Infant Mortality
  • Infant, Extremely Low Birth Weight / blood*
  • Infant, Newborn
  • Male
  • Neonatal Screening / methods
  • Regression Analysis
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Up-Regulation

Substances

  • Biomarkers
  • CCL11 protein, human
  • Chemokine CCL11
  • C-Reactive Protein